Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) has received an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $15.00.

A number of research firms recently weighed in on TRIL. Zacks Investment Research raised Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. HC Wainwright began coverage on Trillium Therapeutics in a report on Monday, July 17th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Cowen and Company reissued a “buy” rating on shares of Trillium Therapeutics in a report on Wednesday, July 5th.

A number of hedge funds and other institutional investors have recently modified their holdings of TRIL. Wells Fargo & Company MN grew its holdings in Trillium Therapeutics by 34.1% in the 1st quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 4,500 shares in the last quarter. Creative Planning grew its holdings in Trillium Therapeutics by 1.1% in the 2nd quarter. Creative Planning now owns 26,400 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 300 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in Trillium Therapeutics in the 2nd quarter valued at $128,000. K2 Principal Fund L.P. acquired a new position in Trillium Therapeutics in the 2nd quarter valued at $264,000. Finally, Victory Capital Management Inc. grew its holdings in Trillium Therapeutics by 40.0% in the 1st quarter. Victory Capital Management Inc. now owns 77,601 shares of the biotechnology company’s stock valued at $479,000 after buying an additional 22,171 shares in the last quarter. 47.97% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 5.40 on Wednesday. The stock has a 50 day moving average of $4.92 and a 200 day moving average of $5.16. The firm’s market cap is $58.29 million. Trillium Therapeutics has a 52 week low of $4.15 and a 52 week high of $16.37.

COPYRIGHT VIOLATION WARNING: “Trillium Therapeutics Inc. (TRIL) Given Average Rating of “Buy” by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/11/trillium-therapeutics-inc-tril-given-average-rating-of-buy-by-brokerages.html.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.